Rating Rationale
April 02, 2019 | Mumbai
Aarti Industries Limited
Rating outlook revised to 'Positive'; ratings reaffirmed
 
Rating Action
Total Bank Loan Facilities Rated Rs.1900 Crore
Long Term Rating CRISIL AA-/Positive (Outlook revised from 'Stable' and rating reaffirmed)
Short Term Rating CRISIL A1+ (Reaffirmed)
 
Rs.100 Crore Non Convertible Debentures CRISIL AA-/Positive (Outlook revised from 'Stable' and rating reaffirmed)
Rs.100 Crore Non Convertible Debentures CRISIL AA-/Positive (Outlook revised from 'Stable' and rating reaffirmed)
Rs.100 Crore Long-Term Borrowing Programme CRISIL AA-/Positive (Outlook revised from 'Stable' and rating reaffirmed)
Rs.400 Crore Commercial Paper CRISIL A1+ (Reaffirmed)
1 crore = 10 million
Refer to annexure for Details of Instruments & Bank Facilities
Detailed Rationale

CRISIL has revised its outlook on the long term bank facility and debt instruments of Aarti Industries Limited (Aarti) to 'Positive' from 'Stable' while reaffirming the rating at 'CRISIL AA-'. The rating on the commercial paper and short-term rating has been reaffirmed at 'CRISIL A1+'.

The outlook revision reflects sharp improvement in the financial risk profile post the equity raising by the company through qualified institutional placement (QIP) of Rs 750 crore as on 23rd March 2019. The fund raising is expected to improve the gearing to below 0.9 times in fiscal 2019 from 1.26 times in fiscal 2018. The ratio of debt to earnings before interest, depreciation, tax, and amortisation (Debt/EBIDTA) which was 3.0 times during 2018, is expected to fall below 2.0 times by fiscal 2021.

Earlier announced capital expenditure (capex) plan of the company to the tune of around Rs 2300 crore over fiscal 2019 to fiscal 2021 in multiple value chains is expected to remain the same post QIP. The capex will mainly be funded out of proceeds of the QIP as well as internal accrual and debt. Overall debt is expected to remain at Rs 2100-2300 crore over medium term, marginally lower than Rs 2400 crore as on December 31st 2018.   
    
Operating performance improved during first nine months of fiscal 2019 reflected in revenue growth of 37% year on year (y-o-y) backed by strong volume growth in specialty chemicals segment and higher revenue contribution from pass through of raw material prices. Operating margin improved to 18.6% in the same period as against 17.8% y-o-y mainly due to better operating leverage from increasing capacity utilizations. Earlier, in fiscal 2018, on a consolidated basis, revenue grew 20% y-o-y and operating margin stood at 18.4%.

Going forward, Aarti's operating performance is expected to remain strong, over medium term supported by improving share of high-margin value-added products and contribution from long term contract manufacturing agreements entered by company in fiscal 2018 and 2019 with global multinational companies (MNCs), which will result in assured business of Rs 14900 crore over the contract period with healthy operating margin. The revenue is expected to grow at around 14% per annum from fiscal 2018 to fiscal 2022, while operating margin is expected to be in the range of 19-21%.

The ratings continue to reflect the Aarti group's established market position, diversified revenue profile, sound operating efficiency, supported by a high level of integration as well as improving financial profile. These strengths are partially offset by large working capital requirement, project related risks and risks related to volatility in commodity prices.

Analytical Approach

For arriving at the ratings, CRISIL has combined the business and financial risk profiles of Aarti and its subsidiaries, Aarti Corporate Services Ltd, Alchemie Europe Ltd, Innovative Envirocare Jhagadia Ltd, Aarti USA Inc, Shanti Intermediaries Pvt Ltd (subsidiary of Aarti Corporate Services Ltd), Nascent Chemical Industries Ltd (subsidiary of Aarti Corporate Services Ltd), Ganesh Polychem Ltd and Aarti Polychem Pvt Ltd. This is because all the companies collectively are referred to as the Aarti group and have significant managerial, operational, and financial linkages.

Please refer Annexure - List of Entities Consolidated, which captures the list of entities considered and their analytical treatment of consolidation.

Key Rating Drivers & Detailed Description
Strengths
Established market position with diversified revenue, higher revenue visibility and healthy profitability
The Aarti group has maintained its dominant market position in the nitro-chloro-benzene (NCB)-based specialty chemicals segment. The group has NCB capacity of 75,000 tonne per annum. Aarti also has presence in other chemical value chains such as toluene, ethylation, sulphur etc. The company has been gradually ramping up capacity utilization of all product lines. Aarti is the largest producer of benzene derivatives in India, and a major player among global manufacturers, with a 25-40% global market share across various products. No single customer or product contributes more than 8% to revenue. The company supplies to diverse end-user industries such as polymer additives, pigments, dyes, paints, pharmaceuticals, agrochemicals, fertilisers, and fast-moving consumer goods, and is insulated from downturn in any particular industry. Also, half its net revenue is from exports, providing geographical diversity. The group maintained a strong revenue growth rate (CAGR of 13% in the past five fiscals). The long term contract manufacturing agreements entered with two global multinational companies will result into assured business and thereby higher revenue visibility over next 20 years. With large capex for improving processes to increase efficiency and greater focus on higher-margin products, the operating margin increased from 15.3% in fiscal 2014 to 18.4% in fiscal 2018 despite volatility in raw material prices. CRISIL believes Aarti will maintain its strong operating performance with healthy growth and profitability over the medium term.

Sound operating efficiency because of continuous investment in process improvement initiatives and high level of integration
The Aarti group has high economies of scale as it is one of the largest producers of NCB in the domestic market and has built up large and flexible manufacturing capacity. Operating efficiency is also supported by strong research and development (R&D) capability. Integrated operations to manufacture higher order derivatives of Benzene, ability to change the product mix according to the demand-supply scenario, and continuous process improvement for maximising the share of value-added benzene derivatives enable Aarti to sustain strong operating efficiency. In addition, the company has increased its captive power generation, which will help improve operating efficiency as well as save on power cost.

* Improving financial risk profile
Aarti has undertaken debt funded capex of about Rs.2200 crore in the past five fiscals. The company also has a capex plan of Rs 2300 crore over fiscal 2019 to fiscal 2021 in multiple value chains to increase market share as well as for long term contracts with global MNCs. Post QIP the additional capex requirement will mainly be funded out of proceeds of QIP and internal accrual, leading to lower dependence on external debt over medium term. The debt protection metrics as well as gearing levels are expected to improve sharply over medium term. Interest coverage and ratio of net cash accrual to adjusted debt which were 5.4 times and 23% are expected to improve to 6.4 times and 33% by fiscal 2021. The ratio of total outside liabilities to adjusted networth (TOL/ANW) is expected to remain below 1.2 times over medium term from 1.62 times in fiscal 2018. The ratio of debt to earnings before interest, depreciation, tax, and amortisation (Debt/EBIDTA) which was 3.0 times during 2018, is expected to fall below 2.0 times by fiscal 2021.

Weakness
Large capacity expansion leading to significant increase in working capital requirement
Revenue growth over the past few fiscals due to continuous capacity addition and volatility in crude-linked raw material prices has increased the group's working capital requirement. This has led to higher dependence on bank borrowings. Also, as the raw materials are predominantly crude derivatives, the company's working capital cycle is susceptible to volatility in crude prices. Its gross current asset days were at 155 days as on March 31, 2018.

* Project Risk and risk related to volatility in commodity prices
The company has been carrying out a large capital expansion over medium term increasing capacities in multiple value chains to increase market share as well as for long term contracts with global MNCs.

Although the capex is in similar product segments, ensuring the projects are completed in stipulated time and within stipulated costs will be critical. Also while the offtake risk is relatively lower due to presence of long term contracts and long term relationships with clients as well as the improved scenario due to supply side reforms in chemical industry in China, overall ramping up of capacities as envisaged, will remain a key monitoring factor.

Additionally, the main raw material, benzene is a crude derivative, prices of which remain susceptible to any sharp volatility in crude prices. While the company has consistently demonstrated its ability to pass on the volatility in raw material prices due to its cost plus business model, which has reflected in consistent operating profitability of 16-20% over last eight fiscals, nevertheless, the company remains exposed to the volatility in commodity prices.
Liquidity

Aarti has adequate liquidity driven by expected cash accruals of more than Rs 550-800 crore per annum in fiscal 2019 to fiscal 2022 and cash and cash equivalents of Rs 58 crore as on September 30, 2018. The bank limit utilization stood at 84% of total working capital limit of Rs 1200 crore on an average over the 12 months ended November 2018. The limits have been enhanced to Rs 1800 crore in December 2018 which enhances the financial flexibility of the company in future. The company has long term repayment obligations around Rs 160-350 crore over 2019 to 2022. CRISIL expects internal accruals, cash & cash equivalents and unutilized bank lines to be sufficient to meet its repayment obligations. The company has a capex plan of Rs 2300 crore over fiscal 2019 to fiscal 2021 which is expected to be mainly out of proceeds of QIP and internal accrual, leading to lower dependence on external debt over medium term.

Outlook: Positive

CRISIL believes the Aarti group will maintain its strong business risk profile over the medium term, backed by revenue diversity and good growth prospects for its high-margin products. This will help in gradual improvement in utilisation of newly added capacity and in maintaining operation margin.

Upside scenario
* Significant and sustained improvement in operating performance
* Improvement in debt metrics backed by increase in cash accruals or equity infusion, for instance gearing improving sustainably below 1 time or Debt/EBITDA below 2 times.

Downside scenario
* Weakening of operating performance leading to lower-than-expected cash accrual or
* Debt protection metrics weaken, most likely because of substantial working capital requirement or higher-than-expected debt-funded capex or acquisition expenditure for instance gearing increasing to 1.5 times or debt/EBIDTA above 3.5 times on sustained basis.

About the Group

Aarti, the flagship company of the Aarti group, manufactures organic and inorganic chemicals at its major facilities in Vapi, Jhagadia, Dahej and Kutch, in Gujarat. It also manufactures active pharmaceutical ingredients at its units in Tarapur and Dombivali in Maharashtra, and at Vapi. Its home and personal care division manufactures surfactants at its units in Silvassa and Pithampur, Madhya Pradesh. The company announced demerger of its home & personal care division into separate entity in June 2018. The group has a strong market position in the nitro-chloro-benzene-based specialty chemicals segment. The company also commissioned greenfield Nitro Toluene facility in Jhagadia, Gujarat in fiscal 2018. In fiscal 2017, it commenced calcium chloride and polydiacetylene (PDA) facilities in Jhagadia, Gujarat and a multipurpose ethylation unit at Dahej, Gujarat. The company also has three full-fledged R&D centres, recognised by the Department of Scientific and Industrial Research, Government of India and is in the process to set up an R&D centre focussed at developing high end value added products and chemistries in specialty chemical segment. In six months ended 30th September 2018, the company did capex of Rs 332 crore.

The other major group companies are mostly into trading of chemicals or are marketing arms of Aarti's products. In June 2018, the company also announced demerger of manufacturing operations of its subsidiary Nascent Chemical Industries Ltd with itself to consolidate the manufacturing operations of the group under one company.

In nine months ended 31th December 2019, company posted operating income of Rs 3646 crore and profit after tax of Rs 345 crore as against operating income of Rs 2670 crore and profit after tax of Rs. 232 crore during similar period of last fiscal.

Key Financial Indicators (Consolidated)
Particulars Unit 2018 2017
Revenue Rs. Cr. 3,806  3,164 
Profit After Tax (PAT) Rs. Cr. 346 328 
PAT Margins % 9.1 10.4
Adjusted Debt/Adjusted Networth Times 1.26 1.10 
Interest coverage Times  5.37  5.59

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL complexity levels are assigned to various types of financial instruments. The CRISIL complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.
Annexure - Details of Instrument(s)
ISIN Name of instrument Date of
Allotment
Coupon
Rate (%)
Maturity date Issue Size
(Rs. Cr)
Rating Assigned
with Outlook
NA Commercial paper NA NA 7-365 days 400 CRISIL A1+
INE769A07043 Non-convertible debentures 31-Jul-2014 11.75% Jun-2019 40 CRISIL AA-/Positive
INE769A07050 Non-convertible debentures 31-Jul-2014 11.75% Jun-2020 40 CRISIL AA-/Positive
INE769A07068 Non-convertible debentures 31-Jul-2014 11.75% Jun-2021 40 CRISIL AA-/Positive
NA Long-Term Borrowing Programme NA NA Mar-2022 100 CRISIL AA-/Positive
NA Cash credit NA NA NA 1080 CRISIL AA-/Positive
NA Letter of credit & bank guarantee NA NA NA 600 CRISIL A1+
NA Proposed cash credit limit NA NA NA 50 CRISIL AA-/Positive
NA Term loan 31_Mar-2017 8.15% Mar-2024 100 CRISIL AA-/Positive
NA Term loan 12-Feb-2014 11% Mar-2021 70 CRISIL AA-/Positive
 
Annexure - List of Entities Consolidated
Entities consolidated
Aarti Corporate Services Ltd Full consolidation
Alchemie Europe Ltd Full consolidation
Innovative Envirocare Jhagadia Ltd Full consolidation
Aarti USA Inc, Full consolidation
Shanti Intermediaries Pvt Ltd Full consolidation
Nascent Chemical Industries Ltd Full consolidation
Ganesh Polychem Ltd Full consolidation
Aarti Polychem Pvt Ltd Full consolidation
Annexure - Rating History for last 3 Years
  Current 2019 (History) 2018  2017  2016  Start of 2016
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Commercial Paper  ST  400.00  CRISIL A1+  06-02-19  CRISIL A1+  09-07-18  CRISIL A1+  25-09-17  CRISIL A1+    --  -- 
            05-01-18  CRISIL A1+           
Long-Term Borrowing Programme  LT  100.00
02-04-19 
CRISIL AA-/Positive  06-02-19  CRISIL AA-/Stable  09-07-18  CRISIL AA-/Stable  25-09-17  CRISIL AA-/Stable  29-09-16  CRISIL AA-/Stable  CRISIL A+/Positive 
            05-01-18  CRISIL AA-/Stable           
Non Convertible Debentures  LT  120.00
02-04-19 
CRISIL AA-/Positive  06-02-19  CRISIL AA-/Stable  09-07-18  CRISIL AA-/Stable  25-09-17  CRISIL AA-/Stable  29-09-16  CRISIL AA-/Stable  CRISIL A+/Positive 
            05-01-18  CRISIL AA-/Stable           
Fund-based Bank Facilities  LT/ST  1300.00  CRISIL AA-/Positive  06-02-19  CRISIL AA-/Stable  09-07-18  CRISIL AA-/Stable  25-09-17  CRISIL AA-/Stable  29-09-16  CRISIL AA-/Stable  CRISIL A+/Positive 
            05-01-18  CRISIL AA-/Stable           
Non Fund-based Bank Facilities  LT/ST  600.00  CRISIL A1+  06-02-19  CRISIL A1+  09-07-18  CRISIL A1+  25-09-17  CRISIL A1+  29-09-16  CRISIL A1+  CRISIL A1 
            05-01-18  CRISIL A1+           
All amounts are in Rs.Cr.
Annexure - Details of various bank facilities
Current facilities Previous facilities
Facility Amount (Rs.Crore) Rating Facility Amount (Rs.Crore) Rating
Cash Credit 1080 CRISIL AA-/Positive Cash Credit 1080 CRISIL AA-/Stable
Letter of credit & Bank Guarantee 600 CRISIL A1+ Letter of credit & Bank Guarantee 600 CRISIL A1+
Proposed Cash Credit Limit 50 CRISIL AA-/Positive Proposed Cash Credit Limit 50 CRISIL AA-/Stable
Term Loan 170 CRISIL AA-/Positive Term Loan 170 CRISIL AA-/Stable
Total 1900 -- Total 1900 --
Links to related criteria
CRISILs Approach to Financial Ratios
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating criteria for manufaturing and service sector companies
Rating Criteria for Chemical Industry
CRISILs Criteria for Consolidation

For further information contact:
Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
naireen.ahmed@crisil.com

Vinay Rajani
Media Relations
CRISIL Limited
D: +91 22 3342 1835
M: +91 91 676 42913
B: +91 22 3342 3000
vinay.rajani@ext-crisil.com

Anuj Sethi
Senior Director - CRISIL Ratings
CRISIL Limited
B:+91 44 6656 3100
anuj.sethi@crisil.com


Gautam Shahi
Director - CRISIL Ratings
CRISIL Limited
B:+91 124 672 2000
gautam.shahi@crisil.com


Omkar Bibikar
Rating Analyst - CRISIL Ratings
CRISIL Limited
D:+91 22 3342 3007
Omkar.Bibikar@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Limited

CRISIL is a leading agile and innovative, global analytics company driven by its mission of making markets function better. We are India’s foremost provider of ratings, data, research, analytics and solutions. A strong track record of growth, culture of innovation and global footprint sets us apart. We have delivered independent opinions, actionable insights, and efficient solutions to over 1,00,000 customers.
 
We are majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.
 
For more information, visit www.crisil.com 


Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK

About CRISIL Ratings
CRISIL Ratings is part of CRISIL Limited (“CRISIL”). We pioneered the concept of credit rating in India in 1987. CRISIL is registered in India as a credit rating agency with the Securities and Exchange Board of India (“SEBI”). With a tradition of independence, analytical rigour and innovation, CRISIL sets the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 24,500 large and mid-scale corporates and financial institutions. CRISIL has also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and microfinance institutions. We also pioneered a globally unique rating service for Micro, Small and Medium Enterprises (MSMEs) and significantly extended the accessibility to rating services to a wider market. Over 1,10,000 MSMEs have been rated by us.


CRISIL PRIVACY
 
CRISIL respects your privacy. We may use your contact information, such as your name, address, and email id to fulfil your request and service your account and to provide you with additional information from CRISIL.For further information on CRISIL’s privacy policy please visit www.crisil.com.


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale that we provide (each a “Report”). For the avoidance of doubt, the term “Report” includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Rating are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL assumes no obligation to update its opinions following publication in any form or format although CRISIL may disseminate its opinions and analysis. CRISIL rating contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way.CRISIL or its associates may have other commercial transactions with the company/entity.

Neither CRISIL nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, “CRISIL Parties”) guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL’s public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about CRISIL ratings are available here: www.crisilratings.com.

CRISIL and its affiliates do not act as a fiduciary. While CRISIL has obtained information from sources it believes to be reliable, CRISIL does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of the respective activity. As a result, certain business units of CRISIL may have information that is not available to other CRISIL business units. CRISIL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html

CRISIL’s rating criteria are generally available without charge to the public on the CRISIL public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL.

All rights reserved @ CRISIL